Jefferies Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Jefferies Group’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-6,000	Closed	-$301	–	1395
2020 Q2	$301	Buy	+6,000	New	+$310K	﹤0.01%	1013
2019 Q3	–	Sell	-7,180	Closed	-$606K	–	2778
2019 Q2	$606K	Buy	7,180 +6,064	+543%	+$545K	﹤0.01%	1568
2019 Q1	$107K	Buy	+1,116	New	+$100K	﹤0.01%	2102
2015 Q3	–	Sell	-91	Closed	-$4K	–	2480
2015 Q2	$4K	Buy	+91	New	+$3.54K	﹤0.01%	3030

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Jefferies Group's ENTA Position: Q3 2020 in Review

Jefferies Group sold out of Enanta Pharmaceuticals (ENTA) in Q3 2020, closing a stake of 6,000 shares — an estimated $301 sold.

Jefferies Group first reported a position in ENTA in Q2 2015 and held it in 4 quarters. The position peaked at $606K in Q2 2019. 172 funds tracked by Wall St. Rank hold ENTA as of Q3 2020.

Jefferies Group reported no remaining Enanta Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Jefferies Group sold 6,000 Enanta Pharmaceuticals shares in Q3 2020, an estimated $301.
Jefferies Group first reported a position in Enanta Pharmaceuticals in Q2 2015 and held it in 4 quarters.
Jefferies Group's Enanta Pharmaceuticals position peaked at $606K in Q2 2019.
172 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2020.

Based on Jefferies Group's 13F filing for Q3 2020, filed 13 Nov 2020.